Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
HS-IDeg and NN-IDeg demonstrated similar efficacy and safety over 18 weeks of treatment in Chinese patients with T2DM who had inadequate responses to OADs for at least 3 months.
Authors
- Yibing Lu
- Chengwei Song (ORCID: https://orcid.org/0000-0003-3578-3650)
- Linong Ji (ORCID: https://orcid.org/0000-0003-1305-1598)
- Yunming Gao (ORCID: https://orcid.org/0000-0002-8307-7219)
- Hongwei Ling (ORCID: https://orcid.org/0009-0007-5702-4969)
- Leili Gao (ORCID: https://orcid.org/0000-0003-4928-9418)
- Wenli Sun (ORCID: https://orcid.org/0000-0002-1705-2996)
- Shu Li (ORCID: https://orcid.org/0000-0003-0350-0353)
- Zhifeng Cheng
- Jie Liu (ORCID: https://orcid.org/0000-0001-5407-3457)
- Jingfang Sun
- Guoqing Ma
- Jianlin Geng
- Haifang Wang (ORCID: https://orcid.org/0000-0001-5706-6703)
- Mei‐Ying Liu (ORCID: https://orcid.org/0000-0003-0454-0752)
Institutions
- Handan College (CN)
- Harbin Medical University (CN)
- Xuzhou Medical College (CN)
- Peking University (CN)
- Jilin Province Tumor Hospital (CN)
- First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN)
- Baogang Group (China) (CN)
- Fourth Affiliated Hospital of Harbin Medical University (CN)
- Peking University People's Hospital (CN)
- The First People’s Hospital of Lianyungang (CN)
- Yueyang Second People's Hospital (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Harrison International Peace Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Huizhou Central People's Hospital (CN)
- Xian Yang Central Hospital (CN)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1080/03007995.2024.2401096
- Citations
- 1
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- Marathon